Sign In
Buy SLGL
$71.50
-2.23 (-3.02%)
At Close: Jun 03, 2026
This detailed market intelligence publication offers valuable insights into the innovative technologies, competitive landscape, and emerging opportunities that are reshaping the global surface enginee
SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know
11:05am, Tuesday, 25'th Feb 2025
Sol-Gel's fourth-quarter 2024 earnings are likely to have gained from higher licensing revenues from its partners.
Is SolGel Technologies (SLGL) a Great Value Stock Right Now?
10:41am, Wednesday, 25'th Dec 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know
01:00pm, Wednesday, 20'th Nov 2024
SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue Estimates
09:11am, Friday, 15'th Nov 2024
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.13.
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
07:00am, Friday, 15'th Nov 2024
Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholders Phase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activated SGT-210 pr
SolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:55am, Tuesday, 17'th Sep 2024
After losing some value lately, a hammer chart pattern has been formed for SolGel Technologies (SLGL), indicating that the stock has found support. This, combined with an upward trend in earnings esti
All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy
01:01pm, Tuesday, 27'th Aug 2024
SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
11:27am, Saturday, 17'th Aug 2024
Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with ov
Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates
09:10am, Friday, 16'th Aug 2024
Sol-Gel Technologies Ltd. (SLGL) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share.
Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
07:00am, Friday, 16'th Aug 2024
Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with ov
Sol-Gel Technologies Announces Management Realignment
07:00am, Monday, 15'th Jul 2024
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Ph
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
07:00am, Monday, 20'th May 2024
Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO® in China, H
NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Pha
Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
07:00am, Monday, 01'st Apr 2024
NESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Pha
